Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3% – Time to Buy?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s share price was up 3% on Monday . The stock traded as high as $11.90 and last traded at $11.93. Approximately 195,038 shares traded hands during trading, a decline of 74% from the average daily volume of 750,368 shares. The stock had previously closed at $11.58.

Analyst Ratings Changes

Several research firms have recently commented on FULC. Leerink Partners set a $20.00 price objective on Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Piper Sandler reissued an “overweight” rating and set a $23.00 price target (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Cantor Fitzgerald lifted their price objective on Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America increased their target price on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Hold” and an average price target of $19.00.

Fulcrum Therapeutics Trading Down 0.3%

The company has a market cap of $612.07 million, a P/E ratio of -9.58 and a beta of 3.17. The firm has a 50 day moving average of $10.48 and a 200-day moving average of $8.56.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total transaction of $165,450.00. Following the completion of the transaction, the director directly owned 484,864 shares of the company’s stock, valued at $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC boosted its stake in Fulcrum Therapeutics by 865.0% during the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock worth $989,000 after buying an additional 308,854 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth about $425,000. Exome Asset Management LLC boosted its stake in shares of Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after purchasing an additional 405,538 shares during the period. Strs Ohio bought a new position in Fulcrum Therapeutics during the 1st quarter valued at about $263,000. Finally, Bailard Inc. purchased a new stake in Fulcrum Therapeutics in the 2nd quarter worth about $185,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.